Related Experiment Video
Updated: Aug 12, 2026
08:47
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Impact of apolipoprotein A5 polymorphisms on insulin sensitivity and beta-cell function
Ken C Chiu1, Yen-Feng Chiu, Avetis Arthur Boyadjian
1Division of Clinical Epidemiology and Preventive Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. kchiu@mednet.ucla.edu
Pancreas
|April 21, 2005
Summary
The V150M polymorphism in the Apolipoprotein A5 (APOA5) gene influences insulin secretion and sensitivity. This genetic variation is a marker for beta-cell function, impacting insulin responses independently.
Area of Science:
- Genetics
- Metabolic Diseases
- Endocrinology
Background:
- Lipid metabolism is crucial for insulin sensitivity and beta-cell function.
- Apolipoprotein A5 (APOA5) plays a key role in lipid metabolism.
- The genetic impact of APOA5 on insulin regulation remains largely unstudied.
Purpose of the Study:
- To investigate the association between APOA5 gene polymorphisms and measures of insulin sensitivity and beta-cell function.
- To examine the influence of V150M and G182C polymorphisms in APOA5 on glucose tolerance and insulin secretion.
Main Methods:
- Studied 67 glucose-tolerant white subjects.
- Assessed insulin sensitivity index (ISI) and first- and second-phase insulin responses (1stIR, 2ndIR) using hyperglycemic clamp.
- Analyzed V150M and G182C polymorphisms in the APOA5 gene.
Main Results:
- The V150M polymorphism was linked to higher 1stIR and 2ndIR (P < 0.002) and lower ISI (P = 0.0135).
- No association was observed with fasting lipids or oral glucose tolerance test results.
- The V150M effects on insulin responses were independent of sex, age, and BMI, but not ISI.
Conclusions:
- The V150M polymorphism in APOA5 independently affects insulin secretion (1stIR and 2ndIR).
- This polymorphism serves as a genetic marker for beta-cell function.
- Further research is needed to elucidate the biological mechanisms underlying these findings.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...